Literature DB >> 27192438

Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.

Laurie Cloutier-Gill1, Evan Wood1,2, Trevor Millar3, Caroline Ferris4, M Eugenia Socias1,2.   

Abstract

BACKGROUND: Opioid use disorders (OUD) translate into major health, social, and economic consequences. Opioid agonist medications, which generally require long-term administration, are the mainstay pharmacological treatment of OUD. However, a large proportion of individuals with OUD either refuse or fail to respond to these therapies. Ibogaine, a naturally occurring substance found in the Tabernanthe iboga plant, has shown potential to bring about transformative or spiritual experiences that have reportedly been associated with long-term abstinece. Although research on ibogaine is limited, an ibogaine subculture persists, offering unregulated ibogaine preparations for the treatment of addiction. CASE
PRESENTATION: We describe the case of a 37-year-old female with a 19-year history of severe OUD achieving an ongoing 18-month period of abstinence following a four-day ibogaine treatment. Her previous longest period of continuous abstinence from opioids was two months while on methadone. No safety issues associated with ibogaine were observed.
CONCLUSIONS: A four-day treatment with ibogaine was succesful in achieving long-term remission of a previously treatment-refractory patient with severe OUD. While rigorous trials are required to establish safety and efficacy, future studies should seek to delineate the potential role of ibogaine or other molecules that may produce transformative experiences for individuals with substance use disorder.

Entities:  

Keywords:  Ibogaine; methadone; methadone maintance therapy; opioid agonist treatment; opioid use disorders

Mesh:

Substances:

Year:  2016        PMID: 27192438      PMCID: PMC4993099          DOI: 10.1080/02791072.2016.1180467

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  15 in total

Review 1.  Psychedelic medicine: a re-emerging therapeutic paradigm.

Authors:  Kenneth W Tupper; Evan Wood; Richard Yensen; Matthew W Johnson
Journal:  CMAJ       Date:  2015-09-08       Impact factor: 8.262

2.  2008 World Drug Report: a more pragmatic approach needed to combat illicit drug use.

Authors:  Vipin M Vashishtha
Journal:  Indian Pediatr       Date:  2008-09       Impact factor: 1.411

3.  Fatalities temporally associated with the ingestion of ibogaine.

Authors:  Kenneth R Alper; Marina Stajić; James R Gill
Journal:  J Forensic Sci       Date:  2012-01-23       Impact factor: 1.832

Review 4.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2014-02-06

Review 5.  Ibogaine in the treatment of substance dependence.

Authors:  Thomas Kingsley Brown
Journal:  Curr Drug Abuse Rev       Date:  2013-03

6.  Diacetylmorphine versus methadone for the treatment of opioid addiction.

Authors:  Eugenia Oviedo-Joekes; Suzanne Brissette; David C Marsh; Pierre Lauzon; Daphne Guh; Aslam Anis; Martin T Schechter
Journal:  N Engl J Med       Date:  2009-08-20       Impact factor: 91.245

7.  The ibogaine medical subculture.

Authors:  Kenneth R Alper; Howard S Lotsof; Charles D Kaplan
Journal:  J Ethnopharmacol       Date:  2007-08-25       Impact factor: 4.360

8.  Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study.

Authors:  I M Maisonneuve; R W Keller; S D Glick
Journal:  Eur J Pharmacol       Date:  1991-06-18       Impact factor: 4.432

Review 9.  The anti-addiction drug ibogaine and the heart: a delicate relation.

Authors:  Xaver Koenig; Karlheinz Hilber
Journal:  Molecules       Date:  2015-01-29       Impact factor: 4.411

10.  Effect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation.

Authors:  Tamara Antonio; Steven R Childers; Richard B Rothman; Christina M Dersch; Christine King; Martin Kuehne; William G Bornmann; Amy J Eshleman; Aaron Janowsky; Eric R Simon; Maarten E A Reith; Kenneth Alper
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

View more
  3 in total

Review 1.  The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).

Authors:  Genís Ona; Juliana Mendes Rocha; José Carlos Bouso; Jaime E C Hallak; Tre Borràs; Maria Teresa Colomina; Rafael G Dos Santos
Journal:  Psychopharmacology (Berl)       Date:  2021-08-18       Impact factor: 4.530

Review 2.  New and Emerging Opioid Overdose Risk Factors.

Authors:  Ralph Foglia; Anna Kline; Nina A Cooperman
Journal:  Curr Addict Rep       Date:  2021-04-22

Review 3.  Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders.

Authors:  Nataliya Vorobyeva; Alena A Kozlova
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.